Nobel laureate Professor Arieh Warshel Joined the SAB of BridGene

Sunnyvale, CA, Dec 7, 2018 – BridGene Biosciences, Inc., a biotechnology company deploying a revolutionary chemoproteomic platform to discover novel targets and develop new therapeutics for unmet medical needs, today announced that Arieh Warshel has joined the Scientific Advisory Board.  SAB provides strategic guidance and direction for research and scientific programs. It plays a key role in guiding and prioritizing BridGene’s research, development and clinical application of BridGene’s IMTAC platform.

“We are honored to have Dr. Warshel available to our distinguished team of scientific advisers and to advise us as we continue to innovate on our research” said Ping Cao, CEO at BridGene. ‘He is a pioneer in modern biophysical chemistry. By drawing on his extensive experience and thought leadership in the field, he will bring both the expertise and invaluable vision to advance our technology and enhance our capabilities in the drug discovery .”

Warshel is known for his work on computational biochemistry and biophysics, in particular for pioneering computer simulations of the functions of biological systems. He received the 2013 Nobel Prize in Chemistry, together with Michael Levitt and Martin Karplus for “the development of multiscale models for complex chemical systems”.

He is a member of many scientific organizations, most importantly:

Elected member of the United States National Academy of Sciences (2009)

Fellow of the Royal Society of Chemistry (2008)

Fellow of the Biophysical Society (2000)

Fellow of the American Association for the Advancement of Science (2012)

Honorary fellow of the Royal Society of Chemistry (2014)

Honorary doctorate of the Faculty of Science and Technology at Uppsala University (2015)

About BridGene Biosciences

BridGene is a biotechnology company dedicated to discovering novel targets and developing new therapeutics for unmet medical needs. BridGene is applying its IMTAC (Isobaric Mass Tagged Affinity Characterization) platform to discover druggable opportunities across the entire proteome. With IMTAC, BridGene is able to expand the therapeutic applications of small molecules drugs to a new horizon.